IL37 and myeloid sarcoma: Interestingly, a recent study reported that serum levels of IL-37 were higher in MS individuals treated with fingolimod as compared to patients receiving no treatment, suggesting that this drug could exert its beneficial actions in MS, at least in part, by increasing the levels of this anti-inflammatory cytokine 22.